Market closedNon-fractional
Affimed/AFMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Affimed
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Ticker
AFMD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Mannheim, Germany
Employees
76
Website
www.affimed.com
Affimed Metrics
BasicAdvanced
$78M
Market cap
-
P/E ratio
-$6.75
EPS
2.04
Beta
-
Dividend rate
Price and volume
Market cap
$78M
Beta
2.04
Financial strength
Current ratio
3.06
Quick ratio
2.685
Long term debt to equity
22.787
Total debt to equity
39.522
Interest coverage (TTM)
-52.01%
Management effectiveness
Return on assets (TTM)
-46.12%
Return on equity (TTM)
-112.37%
Valuation
Price to revenue (TTM)
7.549
Price to book
1.94
Price to tangible book (TTM)
1.94
Price to free cash flow (TTM)
-0.673
Growth
Revenue change (TTM)
-76.27%
Earnings per share change (TTM)
-8.73%
3-year revenue growth (CAGR)
-36.01%
3-year earnings per share growth (CAGR)
22.21%
What the Analysts think about Affimed
Analyst Ratings
Majority rating from 8 analysts.
Affimed Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€400K
-78.95%
Net income
-€20M
-16.87%
Profit margin
-5,050.00%
294.86%
Affimed Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-€2.10
-€2.00
-€1.60
-€1.35
-
Expected
-€1.96
-€1.89
-€1.84
-€1.54
-€1.57
Surprise
7.40%
5.62%
-13.26%
-12.50%
-
Affimed News
AllArticlesVideos
Affimed Reports First Quarter 2024 Financial Results & Business Update
GlobeNewsWire·1 month ago
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
GlobeNewsWire·2 months ago
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Affimed stock?
Affimed (AFMD) has a market cap of $78M as of July 27, 2024.
What is the P/E ratio for Affimed stock?
The price to earnings (P/E) ratio for Affimed (AFMD) stock is 0 as of July 27, 2024.
Does Affimed stock pay dividends?
No, Affimed (AFMD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Affimed dividend payment date?
Affimed (AFMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Affimed?
Affimed (AFMD) has a beta rating of 2.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Affimed stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.